We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

821 hedge funds and large institutions have $59.2B invested in Alnylam Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 224 funds opening new positions, 282 increasing their positions, 223 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

357% more first-time investments, than exits

New positions opened: 224 | Existing positions closed: 49

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

37% more capital invested

Capital invested by funds: $43.1B → $59.2B (+$16.1B)

26% more repeat investments, than reductions

Existing positions increased: 282 | Existing positions reduced: 223

26% more funds holding

Funds holding: 653 → 821 (+168)

2.24% less ownership

Funds ownership: 101.33% → 99.09% (-2.2%)

13% less call options, than puts

Call options by funds: $562M | Put options by funds: $649M

Holders
821
Holders Change
+168
Holders Change %
+25.73%
% of All Funds
10.77%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.17%
New
224
Increased
282
Reduced
223
Closed
49
Calls
$562M
Puts
$649M
Net Calls
-$86.5M
Net Calls Change
-$71M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$1.01B
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$483M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$391M
4
Jane Street
Jane Street
New York
+$381M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$330M

Top Sellers

Rank Fund Capital Flow
1
RP
Regeneron Pharmaceuticals
New York
-$1.24B
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$858M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$548M
4
Winslow Capital Management
Winslow Capital Management
Minnesota
-$479M
5
Dodge & Cox
Dodge & Cox
California
-$357M
Name Holding Trade Value Shares
Change 		Change in
Stake
AWM
801
Abound Wealth Management
Tennessee
$1.65K +$407 +1 +33%
LSA
802
Leonteq Securities AG
Switzerland
$1.37K -$10.6K -26 -90%
RWM
803
Rialto Wealth Management
New York
$1.37K – – –
TPCW
804
TD Private Client Wealth
New York
$1.37K +$814 +2 +200%
BFS
805
Bare Financial Services
Pennsylvania
$1.37K +$1.22K +3 New
Kayne Anderson Rudnick Investment Management
806
Kayne Anderson Rudnick Investment Management
California
$1.23K -$1.22K -3 -60%
PEAK6
807
PEAK6
Illinois
$1.21K +$1.22K +3 New
OAJ
808
Ogorek Anthony Joseph
New York
$1K – – –
SIC
809
SJS Investment Consulting
Ohio
$912 -$814 -2 -50%
LCM
810
Logan Capital Management
Pennsylvania
$912 – – –
CFD
811
Creative Financial Designs
Indiana
$912 +$407 +1 +100%
QWM
812
Quaker Wealth Management
New Jersey
$912 +$407 +1 +100%
BI
813
Binnacle Investments
Iowa
$912 +$814 +2 New
BIM
814
Breakwater Investment Management
Washington
$912 +$814 +2 New
HIA
815
HFM Investment Advisors
New Jersey
$456 -$814 -2 -67%
AWM
816
Activest Wealth Management
Florida
$456 – – –
RJA
817
Ross\Johnson & Associates
Minnesota
$456 – – –
CTC
818
Central Trust Company
Missouri
$456 +$407 +1 New
DCM
819
Davis Capital Management
Florida
$456 +$407 +1 New
RA
820
Rise Advisors
New York
$456 +$407 +1 New
SA
821
Seneschal Advisors
Washington
$456 +$407 +1 New
Norges Bank
822
Norges Bank
Norway
– -$663M -2,032,680 Closed
TLP
823
Tri Locum Partners
New York
– -$29.2M -89,525 Closed
Adage Capital Partners
824
Adage Capital Partners
Massachusetts
– -$27.5M -84,390 Closed
Axa
825
Axa
France
– -$26.9M -82,480 Closed
31 32
33
34 35

ALNY Hedge Fund Activity: Q3 2025 in Review

821 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2025, worth a combined $59.2B — up 37% from $43.1B a quarter earlier.

Buyers outnumbered sellers: 224 funds opened new ALNY positions and 49 closed out — a net gain of 175 holders — while 282 added to existing stakes and 223 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $1.01B. The largest seller was Regeneron Pharmaceuticals, cutting an estimated $1.24B.

  • 821 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2025, up from 653 in Q2 2025.
  • Funds reported $59.2B of Alnylam Pharmaceuticals stock for Q3 2025, up 37% quarter-over-quarter.
  • 224 funds opened new Alnylam Pharmaceuticals positions in Q3 2025 and 49 closed out, a net change of +175 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2025 was JP Morgan Chase, an estimated $1.01B added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2025 was Regeneron Pharmaceuticals, an estimated $1.24B sold.

Based on aggregated 13F filings for Q3 2025.